Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Sleep Disorders Channel is supported through educational grants from Alkermes and Takeda.

VJNeurology is an independent medical education platform. Channel supporters have no influence over the production of content.

Share this video  

Sleep Europe 2026 | Endotype-guided OSA treatment: tirzepatide, AD109 and the move toward combination therapy

Danny Eckert, PhD, Flinders University, Adelaide, Australia, discusses developments in obstructive sleep apnea (OSA) pharmacotherapy and how algorithms developed to detect OSA endotypes are guiding targeted treatment and combination therapy. Prof. Eckert highlights tirzepatide, which has been shown to reduce OSA severity in people with obesity who achieve substantial weight loss. He also discusses AD109, the first targeted therapy for OSA, which showed positive topline results in the Phase III SynAIRgy (NCT05813275) and LunAIRo (NCT05811247) trials and is now under FDA review. This interview took place at Sleep Europe 2026 in Maastricht, the Netherlands.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

So it’s a super exciting time for the field and I just gave a talk then on the different pathophysiological causes or endotypes of sleep apnea and how we’re developing algorithms to automatically detect these from our existing sleep studies and newer approaches. So we’ve now got the tools to be able to automatically get this information with ease from the routine information and what that’s unlocking for us is the ability to then target these various drugs that are emerging...

So it’s a super exciting time for the field and I just gave a talk then on the different pathophysiological causes or endotypes of sleep apnea and how we’re developing algorithms to automatically detect these from our existing sleep studies and newer approaches. So we’ve now got the tools to be able to automatically get this information with ease from the routine information and what that’s unlocking for us is the ability to then target these various drugs that are emerging. So the one that is here now is the injectable tirzepatide It’s the one that’s been studied so far and obese people with sleep apnea can roughly halve your sleep apnea severity in these one-year trials in these folks that obtain substantial weight loss with those incretin agents or in particular tirzepatide. There are other studies underway in that space but beyond that the first targeted therapy for sleep apnea known as AD109, it’s a combination of a noradrenergic agent and an anti-muscarinic to activate the muscles around the airway and reactivate those muscles that lose some of their tone as we go off to sleep. So the core mechanism that’s really causing sleep apnea. Those studies, the Phase III studies, two major Phase III studies showed positive top line results and are now with the FDA and awaiting outcomes as to their approval status in late February. So a very exciting time for the field and there are others, many others that are also targeting those different endotypes that are in development at various stages. So you know they’re the two closest obviously tirzepatide here and with the potential for the other targeted drug therapy to be here early next year. Look I think it’s just an exciting time for the field as these therapies are opening up. We’re understanding more about the different causes, the technology, being able to monitor people over the multiple nights in the home and use that information to really better define what’s going on for the individual and target the therapy including opening up targeted therapies, combination therapies I should say for the first time. You know it’s really exciting so we’re starting to move beyond this sort of one-size-fits-all model to a care model where we know why that individual is getting their sleep apnea and which treatment or treatments may be most appropriate for them based on their individual causes. So very exciting time for the field.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...

Choose your cookie settings

VJNeurology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.